Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development, manufacturing, and potential commercialization of genetic therapies for rare and often fatal diseases with high unmet medical need. The company employs a multi-platform approach using adeno-associated virus (AAV) and lentiviral (LV) vectors to create gene therapy product candidates designed to correct the underlying genetic causes of complex inherited cardiomyopathies and related disorders. Its operations are supported by in-house research and development capabilities and current cGMP manufacturing facilities that enable end-to-end control of clinical production, process development, and scale-up for potential commercialization.

Rocket Pharmaceuticals, Inc. generates revenue primarily through the advancement and potential commercialization of its gene therapy product candidates, which are designed to treat rare genetic diseases. The company does not currently have any approved products on the market and therefore does not generate product sales revenue. Instead, its value is derived from the development progress of its pipeline, potential future product sales, and potential strategic partnerships or transactions for certain non-core programs to enable continued development, regulatory approval, and potential commercialization.

The company operates through the following segments: Cardiovascular Programs, Hematology Programs, and Future Opportunities.

• Cardiovascular Programs: This segment focuses on the development of gene therapies for rare genetic cardiomyopathies using AAV vectors. Key product candidates include RP-A501 for Danon disease, RP-A601 for PKP2-related arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-associated dilated cardiomyopathy. These candidates are administered via intravenous infusion and are designed to deliver functional copies of missing or mutated genes to targeted tissues.

• Hematology Programs: This segment focuses on the development of gene therapies for rare blood disorders using lentiviral (LV) vectors in an ex vivo approach. Key product candidates include KRESLADI™ (RP-L201) for Leukocyte Adhesion Deficiency-I, RP-L102 for Fanconi Anemia, and RP-L301 for Pyruvate Kinase Deficiency. These therapies involve collecting a patient’s hematopoietic stem cells, genetically modifying them with an LV vector in a controlled laboratory environment, and reinfusing them into the patient.

• Future Opportunities: This segment encompasses exploratory preclinical research and development efforts aligned with the company’s strategy to identify and prioritize new gene therapy candidates. Research focuses on complex genetic disorders with differentiated therapies that offer the potential to be first-, best-, or only-in-class, targeting monogenic diseases with on-target mechanisms of action. The segment supports the expansion of the company’s gene therapy platform to additional indications compatible with its technologies and core strategy.

Rocket Pharmaceuticals, Inc. operates in the highly competitive gene therapy industry, where it differentiates itself through its fully integrated model combining in-house R&D and cGMP manufacturing capabilities. The company faces competition from larger biotechnology and pharmaceutical firms, academic institutions, and other gene therapy developers targeting similar rare diseases. Its competitive advantages include its proprietary vector platforms, extensive intellectual property portfolio, regulatory designations such as RMAT, Fast Track, and Orphan Drug, and its focus on potentially curative, one-time treatments for devastating conditions with high unmet need.

Rocket Pharmaceuticals, Inc. serves patients suffering from rare and often fatal genetic diseases, including Danon disease, PKP2-related arrhythmogenic cardiomyopathy, BAG3-associated dilated cardiomyopathy, Leukocyte Adhesion Deficiency-I, Fanconi Anemia, and Pyruvate Kinase Deficiency. The company collaborates with healthcare providers, payors, and patient communities to ensure its therapies address real-world needs, with the ultimate goal of delivering transformative and durable clinical benefits to individuals with life-threatening conditions.